The US FDA's quality metrics program for drug manufacturing facilities may be quiet and potentially undergoing some changes, but has not been abandoned.
Office of Pharmaceutical Quality Director Michael Kopcha said the agency continues to review the myriad of comments received from industry...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?